Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
INDOCO
Mr. Sundeep Vasant Bambolkar · Mumbai, India · 6,000 employees
₹216.69
▼-3.71%Indoco Remedies' shares declined sharply due to a profit decline, with its high P/E and rising debt/equity raising concerns about its valuation and financial health.
Exchange
NSI
Currency
INR
Day range
₹216.03 – ₹222.90
52-week range
₹162.19 – ₹332.20
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis40% confidence
Trading near the lower end of its 1-year range, Indoco Remedies' shares appear overvalued compared to their historical price levels.
34.8% below the 1-year high · trend down
Hedge-fund memo
Today
The stock price declined -3.71% today due to a lack of news.
This week
-5.51% over the past 5 trading days, primarily driven by declining profit.
This month
-14.15% over the past 30 trading days.
Bull thesis
Bear thesis
Hidden risks
News & sentiment
Bullish
20 headlines · 11 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 2 recent quarters (EPS actual vs. consensus).
-1.8513 vs -3.6
48.58% surprise
-0.9545 vs -3
68.18% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| INDOCO | 19.97B | 637.32 | — | 1.39% | 6.80% |
| FDC | 66.34B | 23.58 | 11.81% | 15.73% | 18.90% |
| JBCHEPHARM | 387.93B | 54.22 | 18.69% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 499sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Debt and debt/equity levels
Mitigation: Rising profitability or debt repayment efforts could mitigate this risk.
Competition from other Indian pharmaceutical companies
Mitigation: Indoco Remedies needs to maintain its focus on cost-cutting measures and expanding its product portfolio to remain competitive.
Business intelligence
Competitive moat
Indoco Remedies' strong distribution network and relationships with local and international clients provide a durable competitive advantage in the Indian pharmaceutical market.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Indoco Remedies announces cost-cutting measures and a renewed focus on expanding its product portfolio and international presence.
Thesis builder
Bull case
The company could surprise the market with significant cost-cutting measures and a renewed focus on expanding its product portfolio and international presence.
Base case
We expect the company to maintain its current trajectory of moderate revenue growth and declining profit margins.
Bear case
Indoco Remedies' shares could decline further if the company fails to address its financial health and struggles with competition from other pharmaceutical companies.
Time horizon
Short-term, we expect the shares to trade within the current range, while medium-term risks related to profitability and competition may impact long-term prospects.
Est. CAGR
5-10%
Entry (qual.)
Investors who believe the company can rebound from its current challenges and improve profitability.
Exit (qual.)
Investors who see the company as unable to address its financial health and declining profitability.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how INDOCO fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain INDOCO for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden opportunities
Watch next
We recommend holding the shares to assess how the company responds to the current challenges and whether it can improve profitability.
simplywall.st·1d ago·neutral report
EquityBulls·1d ago·turnaround profit
MarketsMojo·1d ago·weak fundamentals
MarketsMojo·2d ago·mixed signals
scanx.trade·2d ago·profit surges
Sahi·2d ago·debt repayment
scanx.trade·3d ago·neutral report
TradingView·3d ago·strong execution
TradingView·3d ago·margins pressured
Investing.com·3d ago·revenue miss
Business Standard·3d ago·turnaround performance
marketscreener.com·3d ago·neutral report
MarketsMojo·3d ago·price pressure
TradingView·3d ago·revenue up
Business Standard·3d ago·net profit
CNBC TV18·3d ago·swings to profit
Sahi·3d ago·EBITDA rises
scanx.trade·3d ago·management stable
Whalesbook·3d ago·profit rises
MarketsMojo·4d ago·mixed signals
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
| 16.48% |
| -4.80% |
| SHILPAMED | 117.93B | 48.43 | 9.82% | 20.39% | 31.50% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹216.03
Resistance (day/52w high)
₹222.90
Volume
1,43,119
Trend
down
RSI (14)
31
MACD
bearish
MA cross
golden
50-day MA
₹230.04
200-day MA
₹224.97
vs 200-DMA
-3.7%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 40%